Back to results
US 2006/0154271 A1Published application
Enzymatic nucleic acid treatment of diseases or conditions related to levels of IKK-gamma and PKR
AssigneeSirna Therapeutics, Inc.
InventorJames McSwiggen
Life of this patent
Estimating the term…
Abstract
The present invention relates to nucleic acid molecules, including antisense and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, allozymes, aptamers, decoys and siRNA (RNAi), which modulate the expression or function of IKK genes, such as IKK-gamma, IKK-alpha, or IKK-beta, and PKR genes.
Claims16
A chemically modified double stranded siRNA molecule that down regulates expression of a protein kinase PKR gene via RNA interference (RNAi), wherein:
- a) each strand of said siRNA molecule is independently about 18 to about 28 nucleotides in length;
- and
- b) one strand of said siRNA molecule comprises nucleotide sequence having sufficient complementarity to an RNA of said protein kinase PKR gene for the siRNA molecule to direct cleavage of said RNA via RNA interference.
Dependencies are inferred from the claim text.